← Back to Screener
SAB Biotherapeutics, Inc. Common Stock (SABS)
Price$3.86
Favorite Metrics
Price vs S&P 500 (26W)59.38%
Price vs S&P 500 (4W)-6.83%
Market Capitalization$196.16M
P/E Ratio (Annual)14.78x
All Metrics
Book Value / Share (Quarterly)$3.18
P/TBV (Annual)1.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-72.10%
Cash Flow / Share (Quarterly)$-0.96
Price vs S&P 500 (YTD)-1.20%
Net Profit Margin (TTM)-1795.85%
EPS (TTM)$-1.42
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-1.42
EPS (Annual)$0.22
ROI (Annual)8.58%
Net Profit Margin (5Y Avg)-906.73%
Cash / Share (Quarterly)$2.03
P/E Basic Excl Extra (TTM)14.78x
EPS Growth (5Y)-50.72%
P/E Normalized (Annual)14.78x
ROA (Last FY)7.68%
Revenue Growth TTM (YoY)-92.42%
EBITD / Share (TTM)$0.35
ROE (5Y Avg)-60.20%
Operating Margin (TTM)-2388.92%
Cash Flow / Share (Annual)$-0.96
P/B Ratio1.29x
P/B Ratio (Quarterly)1.18x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)142.83x
Net Interest Coverage (TTM)-52.02x
ROA (TTM)12.51%
EV / EBITDA (TTM)15.02x
EPS Incl Extra (Annual)$0.22
Current Ratio (Annual)9.46x
Quick Ratio (Quarterly)9.13x
3-Month Avg Trading Volume0.50M
52-Week Price Return176.98%
P/E Incl Extra (TTM)14.78x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.29
P/S Ratio (Annual)148.34x
Asset Turnover (Annual)0.03x
52-Week High$6.60
Operating Margin (5Y Avg)-1010.02%
EPS Excl Extra (Annual)$0.22
CapEx CAGR (5Y)-40.71%
26-Week Price Return68.12%
Quick Ratio (Annual)9.13x
13-Week Price Return-3.75%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)9.46x
Enterprise Value$188.935
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2579.03%
Cash / Share (Annual)$2.03
3-Month Return Std Dev56.73%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-9.83%
ROE (Last FY)8.76%
Net Interest Coverage (Annual)-80.07x
EPS Basic Excl Extra (Annual)$0.22
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-1.42
Receivables Turnover (Annual)0.00x
ROI (TTM)14.61%
P/S Ratio (TTM)148.29x
Pretax Margin (5Y Avg)-906.71%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.62
Price vs S&P 500 (52W)141.88%
P/E Ratio (TTM)14.78x
Year-to-Date Return2.94%
5-Day Price Return-1.28%
EPS Normalized (Annual)$0.22
ROA (5Y Avg)-35.54%
Net Profit Margin (Annual)-2579.03%
Month-to-Date Return0.52%
Cash Flow / Share (TTM)$-0.47
EBITD / Share (Annual)$0.20
Operating Margin (Annual)-3244.87%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-53.03%
P/E Excl Extra (TTM)14.78x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.42
P/TBV (Quarterly)3.09x
P/B Ratio (Annual)1.18x
Pretax Margin (TTM)-1795.85%
Book Value / Share (Annual)$3.18
Price vs S&P 500 (13W)-6.62%
Beta0.63x
Revenue / Share (TTM)$0.00
ROE (TTM)15.17%
52-Week Low$1.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.29
4.29
4.29
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SABSSAB Biotherapeutics, Inc. Common Stock | 148.29x | -92.42% | — | -50.72% | $3.86 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing targeted human polyclonal antibodies using its DiversitAb platform, which leverages genetically engineered cattle to produce large quantities of fully human antibodies without human plasma or serum. This differentiated approach enables rapid, scalable production for therapeutic applications.